E. Winnerlein-Trump

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

H Tesch, D Hasenclever, M Sieber, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.

V. Diehl, J. Franklin, M. Pfreundschuh, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.